Deal Announcements

Eleven Bio Nets $35 Million Series A Round

Friday, February 19, 2010 5:30:00 AM PDT | VentureDeal Staff

Cambridge, Massachusetts  --  Biotechnology company Eleven Biotherapeutics has secured $35 million in its first round of institutional venture capital investment.

Eleven says that it is developing innovative protein-based therapeutics to treat a variety of autoimmune and blood clotting diseases.

Investors in the round included Flagship Ventures and Third Rock Ventures.  Proceeds purposes from the funding round were not disclosed.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1